AU Patent

AU2019325407B2 — Capsaicin sequential dosing method for treatment of knee joint pain

Assigned to Centrexion Therapeutics Corp · Expires 2025-06-19 · 1y expired

What this patent protects

The invention provides methods and compositions for sequential dosing of capsaicin to treat knee joint pain in a patient, such as knee joint pain due to osteoarthritis, while minimizing transient burning sensation experienced by patients due to capsaicin administration.

USPTO Abstract

The invention provides methods and compositions for sequential dosing of capsaicin to treat knee joint pain in a patient, such as knee joint pain due to osteoarthritis, while minimizing transient burning sensation experienced by patients due to capsaicin administration.

Drugs covered by this patent

Bupivacaine Hydrochloride And Epinephrine (BUPIVACAINE) · Innocoll

Patent Metadata

Patent number: AU2019325407B2
Jurisdiction: AU
Classification: —
Expires: 2025-06-19
Drug substance claim: No
Drug product claim: No
Assignee: Centrexion Therapeutics Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.